自引率: 1.9%
被引量: 1808
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 暂无数据
投稿须知/期刊简介:
Each issue of Neurosurgery Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
期刊描述简介:
Each issue of Neurosurgery Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
-
Molecular Biology of Pituitary Adenomas.
Pituitary adenomas are benign tumors, but still cause significant morbidity and in some cases increases in mortality. Surgical resection is not without risks, and approximately 40% of adenomas are incompletely resected. Medical therapies such as dopamine agonists, somatostatin analogues, and growth hormone antagonists are associated with numerous side effects. Understanding the molecular biology of pituitary adenomas may yield new therapeutic approaches. Additional studies are needed to help determine which genes or pathways are "drivers" of tumorigenesis and should be therapeutic targets. Further studies may also enable pituitary adenoma stratification to tailor treatment approaches.
被引量：8 发表：1970
-
Endovascular management of intracranial dural arteriovenous fistulae.
Endovascular embolization is the primary therapeutic modality for intracranial dural arteriovenous fistulae. Based on access route, endovascular treatment can be schematically divided into transarterial, transvenous, combined, and direct/percutaneous approaches. Choice of access route and technique depends primarily on dural arteriovenous fistulae angioarchitecture, pattern of venous drainage, clinical presentation, and location. Individualized endovascular approaches result in a high degree of cure with a reasonably low complication rate.
被引量：13 发表：1970
-
Passive immunotherapeutic strategies for the treatment of malignant gliomas.
This review provides historical and recent perspectives related to passive immunotherapy for high-grade gliomas. The authors discuss approaches that use lymphokine-activated killer cells, cytotoxic T lymphocytes, and monoclonal antibodies.
被引量：- 发表：2012
-
Clinical trials with immunotherapy for high-grade glioma.
Immunotherapy is a potential new therapeutic option in patients with high-grade gliomas (HGGs). Phase I/II trials have assessed the efficacy of increasing immune activity using vaccines made from lymphokine-activated killer cells, cytotoxic T cells, autologous tumor cells, or dendritic cells. Studies to decrease tumor immunoresistance have focused on cytokine modulation of known immunosuppressive factors in the tumor microenvironment. Several early studies have reported a survival benefit using different forms of immunotherapy. This article discusses past clinical trials using immunotherapy in HGGs, their efficacy, limits, and biologic and clinical design challenges that must be overcome to advance immunotherapy for patients with HGGs.
被引量：6 发表：1970
-
Immunotherapy for glioma: promises and challenges.
Novel immunotherapeutic modalities are being pursed in the treatment of high-grade gliomas. This article explains how tumors suppress immune function in the brain. It specifically describes the ways in which tumors limit effective communication with immune cells, secrete immune-inhibitory cytokines and molecules, and express molecules that induce apoptosis of immune cells. It also defines 3 different immunotherapeutic approaches to counteract this tumor-associated immunosuppression: cytokine therapy, passive immunotherapy (either serotherapy or adoptive immunotherapy), and active immunotherapy. Although immunotherapeutic approaches have met with mixed success so far, immunotherapy continues to be actively pursued because of its potential to attack infiltrating high-grade gliomas.
被引量：15 发表：2012
